Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T0LE
|
|||
| Former ID |
DIB001852
|
|||
| Drug Name |
IRX-4310
|
|||
| Synonyms |
AGN-194310; AGN-4310; ALRT-4310; LGD-4310; NRX-4310; RARa antagonist (oral, chemotherapy-induced neutropenia), Io Therapeutics; Retinoic acid receptor alpha antagonist (oral, chemotherapy-induced neutropenia), Io Therapeutics
Click to Show/Hide
|
|||
| Indication | Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Discontinued in Phase 3 | [1] | |
| Company |
Io Therapeutics Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Retinoic acid receptor (RAR) | Target Info | Antagonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009573) | |||
| REF 2 | An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium. Br J Cancer. 2004 Aug 2;91(3):580-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.